BioNumerik Pharmaceuticals does biopharmaceutical drug development by the numbers. Using a multi-discipline process of identifying potential cancer drugs, the company has brought two candidates into late-stage development. Lead candidate Tavocept, which has FDA fast-track status, may prevent nerve and kidney damage caused by cancer therapies. BioNumerik's Karenitecin candidate is an advanced formulation of an existing cancer drug and is being evaluated for treatment of solid tumors. The firm relies heavily on computer models and simulations to identify promising drug candidates. In addition to its two lead candidates, it has several other potential drugs in pre-clinical research.

Advanced Cell Technology, Inc. is a biotechnology company focused on developing and commercializing human embryonic and adult stem cell technology in the field of regenerative medicine. The Company has acquired, developed and maintain a portfolio of patents and patent applications that form the base for its research and development efforts in the area of embryonic and adult stem cell research. The Company’s technology base, in combination with its know-how, provides an advantage and will facilitate the successful development and commercialization of products for use in treatment of an array of chronic degenerative diseases and in regenerative repair of acute disease, such as trauma, myocardial infarction and burns. The Company’s embryonic stem (ES) cell research programs are divided into three core categories: cellular reprogramming, reduced complexity program, and stem cell differentiation.

IDEXX Laboratories, Inc. company was founded in 1983 and is headquartered in Westbrook, Maine. IDEXX Laboratories, Inc. develops, designs, manufactures, and distributes products for veterinary, and food and water testing markets. It operates in three segments: Companion Animal Group (CAG), Water Quality Products (Water), and Production Animal Segment (PAS). The CAG segment provides point-of-care veterinary diagnostic products, such as instruments and consumables, and rapid assays; and information products and services, and digital radiography systems for veterinarians. This segment also offers commercial veterinary reference laboratory and consulting services to veterinarians in the United States, Canada, Europe, Australia, Japan, and South Africa. The Water segment offers a range of products used in the detection of various microbiological analytes in water to government laboratories, water utilities, and private certified laboratories. The PAS segment provides diagnostic tests and related instrumentation that are used to detect diseases, and to monitor health status in production animals. This segment offers its products primarily to government laboratories, cattle, and poultry and swine producers. IDEXX Laboratories also provides products that test milk for antibiotic residues to dairy producers and processors, as well as to government and food-quality managers. In addition, the company sells point-of-care analyzers and related consumables for use in human medical hospitals and clinics to measure electrolytes, blood gases, acid-base balance, glucose, and ionized calcium, as well as to calculate other parameters, such as base excess and anion gap. It markets and sells its products directly, as well as through independent distributors and other resellers in the Americas, Europe, and the Asia Pacific region.

Tropical Oasis hopes to be exactly that, offering much needed refreshment to bodies in need of liquid. Through its three brands, Tropical Oasis, Liquid Solutions, and Radical Performance Technology, the company offers a variety of nutritional and sports drinks which can boost energy, replenish certain nutrients and vitamins, and assist in weight loss efforts.

Lifecore Biomedical hopes to help bodies plump up, smooth out, and keep moving. Lifecore's hyaluronan division makes products using hyaluronan, a natural lubricating compound found in animal and human connective tissues. The products are used in cataract surgeries, bone grafting, pain treatments for osteoarthritis, and veterinary orthopedics. Hyaluronan is also being tapped for use in cosmetic procedures as a dermal filler (to smooth out wrinkles). Lifecore has supply agreements with Alcon to use its hyaluronan solution in cataract surgery products. In 2008 the firm was taken private by Warburg Pincus.

Catalyst Pharmaceutical Partners, Inc. was founded in 2002 and is based in Coral Gables, Florida. Catalyst Pharmaceutical Partners, Inc., a development-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of prescription drugs for the treatment of drug addiction and obsessive-compulsive disorders. Its products include CPP-109, a chemical compound gamma-vinyl-GABA/vigabatrin, a Phase II clinical trial product for the treatment of cocaine addiction. The company also conducts a Phase II clinical trial of CPP-109 to evaluate its use in the treatment of methamphetamine addiction. In addition, it has a license agreement with Brookhaven Science Associates, LLC on various patents and patent applications relating to the use of vigabatrin as a treatment for cocaine and other addictions.

Cypress Bioscience, Inc. was founded in 1981 and is based in San Diego, California. Cypress Bioscience, Inc. provides therapeutics and personalized medicine services. The company focuses on addressing the needs of physicians and their patients by identifying unmet medical needs in the areas of pain, rheumatology, and physical medicine and rehabilitation, including challenging disorders, such as fibromyalgia and rheumatoid arthritis. It offers Savella, a dual-reuptake inhibitor that preferentially blocks the reuptake of norepinephrine for the management of fibromyalgia. The company provides personalized medicine services, which include tests that are validated analytically and clinically to provide physicians with actionable information to help manage their patients care, including predicting the likelihood of developing disease or optimizing therapy. Its personalized medicine services include Avise PG, a test that supports dose optimization and therapeutic decision making for patients taking methotrexate, a therapy for rheumatoid arthritis (RA); and Avise MCV, a test that aids in the diagnosis and prognosis of RA. The company has a license agreement with Pierre Fabre Medicament to develop and sell products with the compound milnacipran as an active ingredient for various indications in the United States and Canada; a collaboration agreement with Forest Laboratories, Inc. for the development and marketing of milnacipran; and a reformulation and new product agreement with Collegium Pharmaceutical, Inc.

Ranbaxy UK Ltd. company began its operations in Britain in 1994. Ranbaxy UK hopes to run the British generic pharmaceuticals market. Ranbaxy company, a subsidiary of Indian drug firm Ranbaxy Laboratories, offers a wide variety of generic drugs in the UK for central nervous system disorders, cardiovascular diseases, and anti-infectives. Some of the company's products include Easyhaler (an inhaler for respiratory problems), Visclair (for chronic obstructive pulmonary disease), and Distaclor-MR (for respiratory tract infections). Ranbaxy UK represents a major foothold for the group's operations in Europe.

Ondine Biopharma wants to offer an alternative to antibiotics for treating infections. The company is focused on the development and commercialization of its patented light-activated technology, called photodynamic disinfection, as a therapy for bacterial, fungal, and viral infections. Ondine Biopharma is developing a nasal system called MRSAid that incorporates hardware and photosensitizers to help treat often deadly hospital-acquired pathogens, such as staph infections. If commercialized, that product would give the company entry into the hospital infection control market.

Amicus Therapeutics, Inc. company was founded in 2002 and is based in Cranbury, New Jersey. Amicus Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of orally administered, small molecule drugs, known as pharmacological chaperones, for the treatment of a range of human genetic diseases. The Company’s products in development are Amigal (migalastat hydrochloride) for Fabry disease, Plicera (isofagomine tartrate) for Gaucher disease and AT2220 (1-deoxynojirimycin HCl) for Pompe disease. The Company completed its Phase II clinical trials of Amigal and are conducting Phase II clinical trials of Plicera and AT2220.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.